MELBOURNE, Australia and KYOTO, Japan, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) in collaboration with Kanazawa University today announces that the Phase I clinical study of its investigational prostate cancer imaging product in Japanese patients has reported the study results. The study has met its objectives, demonstrating safety and tolerability when using TLX591-CDx (Kit for the preparation of gallium-68 (68Ga) PSMA-11 injection).
This st...
>>> Read more: Japanese Prostate Cancer Imaging Trial Meets Study Objectives
This st...
>>> Read more: Japanese Prostate Cancer Imaging Trial Meets Study Objectives
